JMS
Basic Information
- Stock Code
- 7702
- Industry
- Precision Instruments
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Hiroshima Prefecture
- Establishment Year
- June 1965
- Listing Year
- December 1981
- Official Website
- https://www.jms.cc/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Hogi Medical, Create Medic, Sanyuu, Toami, Nanshin, Manny, Asahi Intecc, Medikit, Daiken Iki, Shofu, Nipro
Overview
Founded in 1965, JMS is a precision medical device manufacturer that boasts a global market share in disposable medical instruments, including AVF needles for dialysis.
Current Situation
JMS achieved consolidated net sales of approximately 58.1 billion yen and net assets of approximately 37 billion yen in the fiscal year ended March 2022, maintaining a solid financial foundation. Its flagship dialysis AVF needle receives high global acclaim and demonstrates strengths in the medical device sector, including infusion sets and extracorporeal circulation equipment. The company is actively expanding its operations into Asia and Europe to grow overseas sales. In recent years, it has focused on developing products that contribute to medical safety and efficiency, earning certification as a Health & Productivity Stock Company, awards from the Japanese Red Cross Society, and other high social recognition. With numerous subsidiaries, it has established a global production and sales network. In 2023, it transitioned to the Tokyo Stock Exchange Standard Market, aiming for mid- to long-term business stability and growth. Moving forward, JMS pursues sustainable growth by advancing medical technology and improving quality of life.
Trivia
Interesting Facts
- Holds significant global share in dialysis AVF needles
- Acquired naming rights for Hiroshima Prefecture cultural facility for regional contribution
- Certified as Health & Productivity Stock Company (White 500)
- Received Silver Medal of Honor from Japanese Red Cross Society
- Actively expanding in Asia and Europe
- Numerous multinational subsidiaries for global deployment
- Roots in 1950s Hiroshima Blood Bank
- Diverse lineup from medical devices to regenerative medicine products
- Active overseas acquisitions and joint ventures since 1990s
- Partnered with Getinge specializing in artificial heart-lung products
- Manufactures medical devices in surgical fields beyond dialysis
- Handles medical nonwoven products
- Focusing on home dialysis support since 2019
- Develops syringe pumps, infusion pumps, and other medical devices
- Corporate number 5240001004384; head office in Naka-ku, Hiroshima City
Hidden Connections
- Differentiated from competitors through medical safety-enhancing product development
- Gained strong local support via Hiroshima cultural facility naming rights
- Built medical field trust through Japanese Red Cross Society collaboration
- Expanded as international medical device brand via Asian market entry
- Strengthened artificial heart-lung market competitiveness via Getinge collaboration
- Rapid local need response enabled by multinational subsidiaries
- Technological superiority in dialysis products forms strong medical institution transaction base
- Health management promotion contributes to higher employee retention
Future Outlook
Growth Drivers
- Dialysis market expansion and aging society progression
- Aggressive overseas medical device market expansion strategy
- Medical product development balancing safety and efficiency
- Regenerative medicine technology advancement and commercialization
- Corporate brand enhancement via health management
- Rising system demand from medical efficiency needs
- Product innovation leveraging digital technology
- Sustainable manufacturing adapting to environmental regulations
- Global sales channel expansion
Strategic Goals
- Maintain top global share in disposable dialysis medical devices
- Achieve approximately 100 billion yen in sales
- Develop and commercialize new medical safety technologies
- Advance sustainability management and environmental impact reduction
- Further expand overseas subsidiaries and local adaptation
- Achieve over 90% employee satisfaction via health management
- Realize sustainable growth through strengthened regional community ties
Business Segments
Medical Device Manufacturing & Sales
- Overview
- Provides a variety of medical instruments to medical institutions, with active overseas expansion.
- Competitiveness
- High-quality products superior in safety and global brand strength
- Customers
-
- General Hospitals
- Specialty Clinics
- Medical Device Distributors
- Medical Wholesalers
- Overseas Medical Institutions
- Public Hospitals
- Clinics
- Products
-
- Dialysis AVF Needles
- Artificial Heart-Lung Machines
- Infusion Sets
- Blood Circuits
- Peritoneal Dialysis Solutions
- Blood Bags
- Medical Nonwoven Products
Pharmaceutical Formulations & Closed Systems
- Overview
- Provides closed drug delivery systems to enhance safety.
- Competitiveness
- Proprietary technology realizing improved medical safety
- Customers
-
- Hospital Pharmacies
- Compounding Pharmacies
- Medical Institutions
- Pharmaceutical Companies
- Products
-
- Anticancer Drug Preparation Closed System
- Prefilled Syringes
- Tubal Nutrition System
Overseas Subsidiaries & Joint Ventures
- Overview
- Deployed in Singapore, the US, China, Thailand, etc., to maintain global competitiveness.
- Competitiveness
- Rapid supply system closely attuned to local needs
- Customers
-
- Overseas Medical Institutions
- Local Medical Device Distributors
- Products
-
- Dialysis Medical Products
- Artificial Heart-Lung Machines
Medical Consumables Supply
- Overview
- Established stable supply system responding to consumables demand at medical sites.
- Competitiveness
- Broad product range and quick responsiveness
- Customers
-
- Hospitals
- Nursing Facilities
- Clinics
- Products
-
- Gloves
- Masks
- Gowns
Competitive Advantage
Strengths
- World top share in dialysis AVF needles
- Extensive production bases domestically and abroad
- Advanced medical safety product development technology
- Sales strength via global network
- Business diversification across multiple product categories
- Long industry experience and reliability
- Health & Productivity Stock Company certification
- Awards from Japanese Red Cross Society
- Robust research and development system
- Regionally rooted company headquartered in Hiroshima
- Stable financial foundation
- Active overseas market expansion
- Collaboration with multinational subsidiaries
- Product development aligned with medical site needs
- Balance of safety and efficiency
Competitive Advantages
- Long-term market leadership in dialysis medical devices
- Comprehensive lineup of disposable medical instruments
- Rapid international response via overseas bases
- Products enhancing medical safety through proprietary technology
- Product portfolio covering diverse medical fields
- High employee motivation backed by health management
- Reliability from certifications in Japan and abroad
- Diversified product development and market expansion strategies
- Extensive transaction history with medical institutions
- Active commitment to sustainable product development
- Advanced quality control system
- METI-sponsored Health & Productivity Stock Company 'White 500' certification
- Comprehensive medical nonwoven products
- Global sales channels
- Competitiveness in advanced and emerging markets
Threats
- Market impact from medical system changes
- Burden of complying with strengthened international medical regulations
- Accelerated technological innovation by competitors
- Rising raw material costs due to exchange fluctuations
- Supply-demand shifts from pandemics and social impacts
- Raw material supply instability risks
- Intensified competition from new entrants
- Overseas business risks from international instability
- Potential product recalls or quality issues
- Increased costs from stricter environmental regulations
- Risk of delayed adaptation to technical standard changes
- Fierce price competition in medical device market
Innovations
2023: Tokyo Stock Exchange Market Change
- Overview
- Changed from Prime Market to Standard Market segment.
- Impact
- Enhanced market transparency and diversified shareholder base
2022: Artificial Heart-Lung Products Certified as 'Izumo Brand Product'
- Overview
- Improved product brand value through regional brand certification.
- Impact
- Strengthened recognition and trust domestically and internationally
2021: Product Supply Agreement with Getinge
- Overview
- Established mutual product supply framework for artificial heart-lung products.
- Impact
- Expanded product lineup and market competitiveness
2020: Received Silver Medal of Honor from Japanese Red Cross Society
- Overview
- Award for outstanding social contribution achievements.
- Impact
- Elevated corporate image and social credibility
2020: Continued Health & Productivity Stock Company Certification
- Overview
- Maintained White 500 certification while advancing health management.
- Impact
- Improved employee satisfaction and work environment
Sustainability
- Continued Health & Productivity Stock Company 'White 500' certification
- Strengthened product development for medical safety improvement
- Regional contributions via naming rights for cultural facilities
- Advancement of regenerative medicine product R&D
- Environmental impact reduction measures at production sites